MarketPulse

dry eye disease

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Johnson Fistel, Pllp

Aldeyra Stock Plummets 70% After FDA Rejection; Law Firm Eyes Securities Claims

Johnson Fistel investigates Aldeyra Therapeutics after FDA rejects lead drug reproxalap. Stock tumbles over 70% on March 17, 2026 announcement.
ALDXstock declineinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Harrow to Release 2025 Financial Results on March 2

Harrow Health will release 2025 financial results March 2, 2026, reaffirming $270-$280 million revenue guidance and highlighting its expanding pharmaceutical portfolio.
HROWfinancial resultsrevenue guidance